List of Sorilux drug patents

Sorilux is owned by Mayne Pharma.

Sorilux contains Calcipotriene.

Sorilux has a total of 2 drug patents out of which 0 drug patents have expired.

Sorilux was authorised for market use on 06 October, 2010.

Sorilux is available in aerosol, foam;topical dosage forms.

Sorilux can be used as use of a calcipotriene containing foam for the treatment of psoriasis; use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 4 years and older, use of a calcipotriene containing foam for the treatment of psoriasis; use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 18 years and older; use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 4 years and older.

The generics of Sorilux are possible to be released after 07 May, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629128 MAYNE PHARMA Vitamin formulation
May, 2026

(3 years from now)

US8263580 MAYNE PHARMA Vitamin formulation
May, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Nov 5, 2022

Drugs and Companies using CALCIPOTRIENE ingredient

Market Authorisation Date: 06 October, 2010

Treatment: Use of a calcipotriene containing foam for the treatment of psoriasis; Use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 18 years and older; Use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 4 years and older

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage

SORILUX family patents

7

United States

4

Australia

4

Spain

4

European Union

2

Poland

2

New Zealand

2

Canada

2

Japan

1

Austria

1

IB

1

Denmark

1

Brazil

1

Portugal

1

Germany

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic